We then treated the FRO cells transfected with the empty vector (FRO pKLO.1) and FRO shHMGA1 cells with doxorubicin, that is currently used in the treatment of anaplastic thyroid carcinoma [12] and LBH589 (aka Panobinostat), an inhibitor of HDAC proteins currently undergoing a clinical trial in patients with metastatic medullary thyroid cancer or radioiodine-resistant differentiated thyroid cancer (ClinicalTrials.gov Identifier:NCT01013597). Here, HDAC9 is linked to differentiated thyroid carcinoma.